Genesis Asset Managers Llp increased its stake in Yandex (YNDX) by 1536.83% based on its latest 2018Q3 regulatory filing with the SEC. Genesis Asset Managers Llp bought 3.33M shares as the company’s stock declined 7.95% with the market. The institutional investor held 3.54 million shares of the programming company at the end of 2018Q3, valued at $116.04M, up from 216,475 at the end of the previous reported quarter. Genesis Asset Managers Llp who had been investing in Yandex for a number of months, seems to be bullish on the $9.21B market cap company. The stock increased 2.98% or $0.82 during the last trading session, reaching $28.38. About 566,105 shares traded. Yandex N.V. (NASDAQ:YNDX) has declined 15.48% since December 28, 2017 and is downtrending. It has underperformed by 15.48% the S&P500. Some Historical YNDX News: 30/05/2018 – Boundless to Host Upcoming Roundtable Webinar on Boundless Anywhere; 26/05/2018 – YANDEX WOULD ONLY SELL SMALL STAKE IF IPO OF UBER JV HELD: RIA; 27/04/2018 – SBERBANK, YANDEX COMPLETED DEAL FOR YANDEX.MARKET JV; 25/04/2018 – Yandex Cash, Cash Equivalents and Term Deposits $1.66B as of March 31; 04/04/2018 – YNDX, MA, FB: #NewsSatellite Russians will be able to transfer money via instant messengers; 29/05/2018 – Russian search giant Yandex has launched its own home assistant smart speaker as it looks to take on the likes of the Amazon Echo and Google Home; 24/05/2018 – PROTEK PAO PRTK.MM AND YANDEX.MARKET SIGN AGREEMENT TO DEVELOP CATEGORY HEALTH ON NEW MARKETPLACE OF SBERBANK AND YANDEX; 09/03/2018 – YANDEX YNDX.O : MORGAN STANLEY RAISES TARGET PRICE TO $47 FROM $40; 25/04/2018 – YANDEX 1Q REV. $464.0M; 08/05/2018 – Fosun International/Yandex Story Published in Error (Correct)
Oakworth Capital Inc decreased its stake in Pfizer Inc (PFE) by 30.92% based on its latest 2018Q3 regulatory filing with the SEC. Oakworth Capital Inc sold 59,499 shares as the company’s stock rose 5.56% while stock markets declined. The institutional investor held 132,901 shares of the health care company at the end of 2018Q3, valued at $5.86M, down from 192,400 at the end of the previous reported quarter. Oakworth Capital Inc who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $251.34 billion market cap company. The stock increased 1.47% or $0.63 during the last trading session, reaching $43.48. About 11.42 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 25.07% since December 28, 2017 and is uptrending. It has outperformed by 25.07% the S&P500. Some Historical PFE News: 23/03/2018 – Pfizer Closes Below 200-Day Moving Average: Technicals; 01/05/2018 – Pfizer 1Q Essential Health Rev $5.08B; 26/04/2018 – Pfizer Hosts Annual Meeting of Shareholders; 23/03/2018 – PFIZER INC – STUDY DID NOT MEET ITS PRIMARY ENDPOINT; 23/03/2018 – STAT Plus: Pharmalittle: Glaxo drops out of bidding for Pfizer consumer unit; Trump policy could hike prices for biosimilars; 01/05/2018 – Pfizer Sales Disappoint as Investors Wait for Strategic M&A; 23/03/2018 – GLAXOSMITHKLINE DID NOT PUT IN A FINAL BID FOR PFIZER’S CONSUMER HEALTHCARE UNIT – SOURCE FAMILIAR WITH SITUATION; 07/05/2018 – PFIZER INDIA QTR REVENUE 5.2B RUPEES; 05/03/2018 – PFIZER INC – LITTMAN WAS ALSO APPOINTED TO CORPORATE GOVERNANCE AND SCIENCE AND TECHNOLOGY COMMITTEES OF PFIZER’S BOARD; 19/03/2018 – U.S. FDA GRANTS PRIORITY REVIEW FOR A SNDA (SNDA) FOR XTANDI®
Among 11 analysts covering Yandex N.V. (NASDAQ:YNDX), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Yandex N.V. had 30 analyst reports since July 31, 2015 according to SRatingsIntel. As per Tuesday, October 6, the company rating was maintained by Deutsche Bank. Deutsche Bank maintained the shares of YNDX in report on Thursday, April 19 with “Buy” rating. Citigroup upgraded the stock to “Buy” rating in Monday, March 14 report. The firm earned “Buy” rating on Tuesday, October 23 by Deutsche Bank. The firm has “Buy” rating by Citigroup given on Thursday, March 29. The firm has “Buy” rating given on Monday, July 18 by HSBC. The rating was maintained by Bank of America on Friday, November 2 with “Buy”. The firm has “Hold” rating by Zacks given on Tuesday, August 4. The firm has “Outperform” rating given on Friday, December 30 by Credit Suisse. Deutsche Bank maintained the stock with “Buy” rating in Tuesday, October 30 report.
Genesis Asset Managers Llp, which manages about $36.75B and $3.13B US Long portfolio, decreased its stake in Pricesmart Inc. (NASDAQ:PSMT) by 91,900 shares to 1.20 million shares, valued at $97.45 million in 2018Q3, according to the filing. It also reduced its holding in Credicorp Ltd (NYSE:BAP) by 257,394 shares in the quarter, leaving it with 935,924 shares, and cut its stake in Embotelladora Andina Ads Rep B.
More notable recent Yandex N.V. (NASDAQ:YNDX) news were published by: Nasdaq.com which released: “Why Yandex Stock Just Dropped Another 9% – Nasdaq” on October 19, 2018, also Nasdaq.com with their article: “Technology Sector Update for 10/29/2018: YNDX, NXPI, TSEM – Nasdaq” published on October 29, 2018, Nasdaq.com published: “Yandex (YNDX) Earnings Miss, Revenues Beat Estimates in Q3 – Nasdaq” on October 30, 2018. More interesting news about Yandex N.V. (NASDAQ:YNDX) were released by: Seekingalpha.com and their article: “Yandex says it regularly receives offers after Sberbank denial – Seeking Alpha” published on October 22, 2018 as well as Nasdaq.com‘s news article titled: “Why Is Yandex (YNDX) Up 5.5% Since Last Earnings Report? – Nasdaq” with publication date: November 28, 2018.
Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 29. They expect $0.64 EPS, up 3.23% or $0.02 from last year’s $0.62 per share. PFE’s profit will be $3.70B for 16.98 P/E if the $0.64 EPS becomes a reality. After $0.78 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -17.95% negative EPS growth.
Since July 20, 2018, it had 0 insider buys, and 2 sales for $1.92 million activity. 40,381 shares valued at $1.50M were sold by SUSMAN SALLY on Friday, July 20.
More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Streetinsider.com which released: “Pfizer (PFE) Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Discontinued Due to Futility – StreetInsider.com” on December 20, 2018, also Benzinga.com with their article: “Dan Nathan Sees Unusual Options Activity In Pfizer (NYSE:PFE) – Benzinga” published on December 19, 2018, Seekingalpha.com published: “European advisory group backs Pfizer’s Avastin biosimilar – Seeking Alpha” on December 14, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: Steady As She Goes – Seeking Alpha” published on December 20, 2018 as well as Streetinsider.com‘s news article titled: “Pfizer (PFE) Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV – StreetInsider.com” with publication date: December 14, 2018.
Among 23 analysts covering Pfizer (NYSE:PFE), 8 have Buy rating, 1 Sell and 14 Hold. Therefore 35% are positive. Pfizer had 89 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, October 31, the company rating was maintained by Credit Suisse. The firm has “Buy” rating by Jefferies given on Monday, June 20. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, January 31. The company was maintained on Tuesday, November 3 by Argus Research. The firm has “Hold” rating by Berenberg given on Thursday, May 12. Goldman Sachs maintained it with “Neutral” rating and $35 target in Monday, April 18 report. Jefferies downgraded Pfizer Inc. (NYSE:PFE) on Thursday, October 13 to “Hold” rating. The firm earned “Neutral” rating on Wednesday, November 25 by SunTrust. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) on Tuesday, October 31 with “Buy” rating. The company was downgraded on Wednesday, November 2 by BMO Capital Markets.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.